Orum Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
29
- Stock Symbol
-
475830
- Share Price
-
$11.24
- (As of Friday Closing)
Orum Therapeutics General Information
Description
Orum Therapeutics Inc is a biotechnology company that develops anticancer drugs with the technology to attach novel drug payloads to ADC. It can develop all three components of ADC, which consist of antibodies, payloads, and linkers, in-house. The group pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, thereby improving the therapeutic window of drugs. Its services include the modeling, research, development, and testing of pharmaceuticals and treatments for such diseases for Orum's partners and licensees. The pipeline products are TPD2GSPT1, TPD2PROTAb, and TPS2Cbl-b.
Contact Information
Website
www.orumrx.comCorporate Office
- 2nd Floor
- 281-25 Munji-ro, Yuseong-Gu
- Daejeon, Yuseong-Gu 34050
- South Korea
Corporate Office
- 2nd Floor
- 281-25 Munji-ro, Yuseong-Gu
- Daejeon, Yuseong-Gu 34050
- South Korea
Orum Therapeutics Stock Performance
As of 13-Nov-2026, Orum Therapeutics’s stock price is $11.24. Its current market cap is $244M with 21.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $11.24 | $11.09 | $10.12 - $100.95 | $244M | 21.7M | 278K | $0.58 |
Orum Therapeutics Financials Summary
As of 30-Jun-2026, Orum Therapeutics has a trailing 12-month revenue of $27.9K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 672,830 | 1,683,447 | ||
| Revenue | 28 | 17 | 15,322 | 103,574 |
| EBITDA | 13,223 | (28,179) | (2,808) | 54,118 |
| Net Income | 12,755 | (29,491) | (4,207) | 52,176 |
| Total Assets | 189,236 | 117,586 | 104,439 | 125,542 |
| Total Debt | 62,344 | 17,707 | 19,233 | 20,082 |
Orum Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Orum Therapeutics Comparisons
Industry
Financing
Details
Orum Therapeutics Competitors (7)
One of Orum Therapeutics’s 7 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Sanofi | Corporation | Gentilly, France | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA |
Orum Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Orum Therapeutics Patents
Orum Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026069278-A1 | Anti-cd123 antibodies and neodegrader conjugates | Pending | 30-Sep-2024 | ||
| AU-2023358091-A1 | Neodegrader conjugates | Pending | 06-Oct-2022 | ||
| EP-4598587-A1 | Neodegrader conjugates | Pending | 06-Oct-2022 | ||
| US-20260131015-A1 | Neodegrader conjugates | Pending | 06-Oct-2022 | ||
| WO-2024075080-A1 | Neodegrader conjugates | Inactive | 06-Oct-2022 | A61K47/6889 |
Orum Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Orum Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
Orum Therapeutics FAQs
-
When was Orum Therapeutics founded?
Orum Therapeutics was founded in 2016.
-
Where is Orum Therapeutics headquartered?
Orum Therapeutics is headquartered in Daejeon, South Korea.
-
What is the size of Orum Therapeutics?
Orum Therapeutics has 29 total employees.
-
What industry is Orum Therapeutics in?
Orum Therapeutics’s primary industry is Drug Delivery.
-
Is Orum Therapeutics a private or public company?
Orum Therapeutics is a Public company.
-
What is Orum Therapeutics’s stock symbol?
The ticker symbol for Orum Therapeutics is 475830.
-
What is the current stock price of Orum Therapeutics?
As of 13-Nov-2026 the stock price of Orum Therapeutics is $11.24.
-
What is the current market cap of Orum Therapeutics?
The current market capitalization of Orum Therapeutics is $244M.
-
What is Orum Therapeutics’s current revenue?
The trailing twelve month revenue for Orum Therapeutics is $27.9K.
-
Who are Orum Therapeutics’s competitors?
Astellas Pharma, Sanofi, Amgen, Genetix Biotherapeutics, and Genentech are some of the 7 competitors of Orum Therapeutics.
-
What is Orum Therapeutics’s annual earnings per share (EPS)?
Orum Therapeutics’s EPS for 12 months was $0.58.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
